A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-31 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Polymeric monoliths as they exist today were developed independently by three different labs in the late 1980s led by Hjerten, Svec, and Tennikova. Simultaneously, bioseparations became increasingly important, and monolith technologies proved beneficial in biotechnology separations. Though industry focus in the 1980s was on biotechnology, focus in the 1990s shifted to process engineering. While mainstream chromatographers were using 3μm particulate columns, sub-2μm columns were in research phase. The smaller particles meant better resolution and shorter run times; there was also an associated increase in backpressure. In order to withstand the pressure, a new field of chromatography came into being: UHPLC or UPLC- ultra high pressure liquid chromatography. The new instruments were able to endure pressures of up to 15,000 pounds per square inch (1,000 bar), as opposed to conventional machines, which, as previously state, can hold up to 5,000 pounds per square inch (340 bar). UPLC is an alternative solution to the same problems monolithic columns solve. Similarly to UPLC, monolith chromatography can help the bottom line by increasing sample throughput, but without the need to spend capital on new equipment. In 1996, Nobuo Tanaka, at the Kyoto Institute of Technology, prepared silica monoliths using a colloidal suspension synthesis (aka “sol-gel”) developed by a colleague. The process is different from that used in polymeric monoliths. Polymeric monoliths, as mentioned above, are created in situ, using a mixture of monomers and a porogen within the column tubing.
17 February Freud under Analysis, historian Peter Gay; psychiatrist Joseph Wortis; the Freud Museum in north-west London; his friend Josef Breuer; his 1895 book Studies on Hysteria; psychologist Frank Sulloway; psychology writer Jeffrey Moussaieff Masson; psychiatrist Jacob Arlow; his 1905 Three Essays on the Theory of Sexuality; the Berlin Psychoanalytic Institute opened in 1920, and he had founded the Deutsche Psychoanalytische Gesellschaft; Abraham Brill; in October 1952 psychologist Hans Eysenck wrote in the Journal of Consulting and Clinical Psychology; Hungarian psychiatrist Thomas Szasz; the Yale Child Study Center; psychologist Jerome Kagan; Francis Crick disputed Freud; Freud moved to England in 1938. A US production, produced by Ben Gooder, directed by Susanne Simpson, made by WGBH and Uden Associates 23 July Mission to Mars, astrogeologist Harold Masursky; Carol Stoker from NASA Ames; planetary geologist Alfred McEwen; German Jesco von Puttkamer and how the space station would be ready by 1994; Gentry Lee of JPL; Jonathan Eberhart and his song about the atmosphere of Mars. Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 30 July Playing with Fire, about the Bradford City stadium fire on Saturday 11 May 1985; it featured the Woolworths fire of 8 May 1979, in central Manchester. Produced by Michael Blakstad, directed by Patrick Fleming, made by Workhouse Productions
== Evolution of neuropeptide signaling == Peptides are ancient signaling systems that are found in almost all animals on Earth. Genome sequencing reveals evidence of neuropeptide genes in Cnidaria, Ctenophora, and Placozoa, some of the oldest living animals with nervous systems or neural-like tissues. Recent studies also show genomic evidence of neuropeptide processing machinery in metazoans and choanoflagellates, suggesting that neuropeptide signaling may predate the development of nervous tissues. Additionally, Ctenophore and Placozoa neural signaling is entirely peptidergic and lacks the major amine neurotransmitters such as acetylcholine, dopamine, and serotonin. This also suggests that neuropeptide signaling developed before amine neurotransmitters.
Sources: en.wikipedia.org
Marine carbon is further separated into particulate and dissolved phases. These pools are operationally defined by physical separation – dissolved carbon passes through a 0.2 μm filter, and particulate carbon does not. There are two main types of inorganic carbon that are found in the oceans:
== Biochemistry == Androgens like testosterone are responsible for penis enlargement and elongation during puberty. Penis size is positively correlated with increasing testosterone levels during puberty. But after puberty, administration of testosterone does not affect penis size, and androgen deficiency in adult men only results in a small decrease in size. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are also involved in penis size, with deficiency (such as that observed in growth hormone deficiency or Laron syndrome) at critical developmental stages having the potential to result in micropenis.
Eannatum, the ensi of Lagash, who was granted might by Enlil, who constantly is nourished by Ninhursag with her milk, whose name Ningirsu had pronounced, who was chosen by Nanshe in her heart, the son of Akurgal, the ensi of Lagash, conquered the land of Elam, conquered Urua, conquered Umma, conquered Ur. At that time, he built a well made of baked bricks for Ningirsu, in his wide temple courtyard. Eananatum's god is Shulutula. Then did Ningirsu love Eannatum". However, revolts often arose in parts of his empire. During Eannatum’s reign, many temples and palaces were built, especially in Lagash. The city of Nina, which has been identified with the site of Tell-Zurghul, was rebuilt, with many canals and reservoirs being excavated.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.